BMY today
$62.32-$0.59 (-0.94%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourBullish
15 minBullish
5 minBearish
Daily trend turns down below $56.15
Key levels
Resistance$65.54
Resistance$63.15
Support$61.30
Support$58.44
Latest news & SEC filings
ProductBeeline Medicines Gives Phase 2 Data for Afimetoran
DealBristol Myers Squibb makes milestone payment to Editas Medicine
All BMY news →About Bristol Myers Squibb
Bristol Myers Squibb is a biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines. Its therapies target cancer, blood disorders, immune conditions, heart disease, and neurological and psychiatric illnesses, with products including Opdivo, Eliquis, Revlimid, and Breyanzi. The company sells its medicines around the world, primarily through intermediaries that move drugs to pharmacies, hospitals, and clinics. It has manufacturing sites in the United States, Puerto Rico, the Netherlands, Ireland, and Switzerland.
Based on the company's 10-K filed Feb 11, 2026.
NYSE · Healthcare
BRISTOL MYERS SQUIBB CO (BMY)
What Is the Price Target for BMY?
SEPT Low Target
$40.00
SEPT Mid Target
$65.00
SEPT High Target
$78.00
Analyst Consensus
$65.00
Is BMY a Buy or Sell Right Now?
Thesis
- •Revenue growing -0.2% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BMY.
Start Free Trial →Is BMY Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$66.50
50
Moat Score
NARROW
7/9
Piotroski Score
2.0
Altman Z-Score
What Is Smart Money Doing with BMY?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
BUYING
3 buys / 5 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Haller Julia A | director | Sale | 3,800 | $241K | Nov 5, 2026 |
| Lenkowsky Adam | officer | Buy | 7,522 | - | Nov 3, 2026 |
| Lenkowsky Adam | officer | Sale | 3,848 | $237K | Nov 3, 2026 |
| Shanahan Karin | officer | Buy | 6,281 | - | Nov 1, 2026 |
| Shanahan Karin | officer | Sale | 3,213 | $201K | Nov 1, 2026 |
| Meyers Gregory Scott | officer | Buy | 6,281 | - | Nov 1, 2026 |
| Meyers Gregory Scott | officer | Sale | 2,665 | $167K | Nov 1, 2026 |
| BOERNER CHRISTOPHER S. | director officer | Buy | 2,964 | - | Nov 1, 2026 |
| BOERNER CHRISTOPHER S. | director officer | Buy | 406 | - | Nov 1, 2026 |
| BOERNER CHRISTOPHER S. | director officer | Sale | 1,724 | $108K | Nov 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BMY Growth Story
Revenue YoY
-0.2%
3yr Revenue CAGR
1.4%
EPS Growth YoY
178.46%
FCF Growth YoY
-7.9%
Revenue Trend
ACCELERATING
Dark Pool Trades for BMY
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BMY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:08 | $62.91 | 7,472 | $$470K | SELL |
| 21:28:25 | $62.91 | 31,860 | $$2.0M | BUY |
| 21:21:59 | $62.91 | 1,835 | $$115K | BUY |
| 21:03:26 | $62.91 | 136,392 | $$8.6M | BUY |
| 21:00:27 | $62.91 | 1,000 | $$63K | BUY |
5 dark pool trades shown · $$11.2M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for BMY
PREVIEWSEPT Investing provides real-time options flow tracking for BMY, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $60 | Nov 13 | 2 | $$90 | 10 | SWEEP |
| PUT | $60 | Nov 13 | 2 | $$9 | 1 | SWEEP |
| PUT | $60 | Nov 13 | 2 | $$90 | 10 | SWEEP |
| PUT | $60 | Nov 13 | 2 | $$9 | 1 | SWEEP |
| PUT | $60 | Nov 13 | 2 | $$45 | 5 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BRISTOL MYERS SQUIBB CO (BMY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BMY — frequently asked questions
What is BMY stock price today?
BRISTOL MYERS SQUIBB CO (BMY) is at $62.32, down 0.94% (-$0.59) at the Nov 12, 2026 close.
Why is BMY stock moving today?
Latest BMY news — Nov 11, 2026: Beeline Medicines Gives Phase 2 Data for Afimetoran · Nov 9, 2026: Bristol Myers Squibb makes milestone payment to Editas Medicine
Why did BMY stock move on Oct 8, 2026?
Bristol Myers Squibb shares closed at $59.58, up 0.81% on volume of 12.86 million shares, as investors reacted to positive clinical news. The company announced that its Zenbexus combination therapy showed a 51% lower risk of myeloma progression or death compared to standard of care in a Phase 3 trial.
What is the BMY price target?
The average analyst price target for BMY is $65.00, ranging from $40 to $78, based on 13 analysts. Latest: Morgan Stanley maintains on Oct 30, 2026.
What do analysts rate BMY?
Analyst ratings for BMY: 1 Buy, 16 Hold, 2 Sell — consensus Hold.
Did BMY beat earnings?
BMY last reported on Oct 29, 2026: EPS $1.35 vs $1.10 expected — a beat of 22.7%.
What is BMY's P/E ratio?
BMY trades at a P/E of 13.9 vs a Healthcare average of 17.3.
Does BMY pay a dividend?
Yes. BMY's dividend yield is 4.58%.
How much debt does BMY have?
BRISTOL MYERS SQUIBB CO reported $42.6B of debt and $9.6B of cash (Sep 30, 2026).
What are BMY support and resistance levels?
Support: $61.30, $58.44, $56.15. Resistance: $63.15, $65.54, $68.24.
What are insiders doing with BMY?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on BMY?
Nov 11, 2026: Beeline Medicines Gives Phase 2 Data for Afimetoran · Nov 9, 2026: Bristol Myers Squibb makes milestone payment to Editas Medicine